The rising incidence of chronic diseases such as cervical and vaginal cancer are expected to drive growth of HPV testing and Pap test market. According to the National Cervical Cancer Coalition 2017, around 12,000 women are diagnosed with cervical cancer per year in the U.S. Moreover, the American Sexual Health Association (ASHA) suggests that cervical cancer is amongst one of the most preventable types of cancer. These cancers can be prevented through early detection and treatment of abnormal cell changes that occurs in the cervix prior to the development of cervical cancer cells.
Request Sample Copy of HPV and Pap Testing Market Report(Including full TOC, Graphs, Sample Data, and Tables) @ https://www.coherentmarketinsights.com/insight/request-sample/1733
Moreover, new product launch in improving the existing accuracy of HPV testing is also expected to drive growth of global HPV testing and Pap test market. For instance, in June 2016, QIAGEN N.V launched the QIAsure Methylation Test, for determining risk of development of cervical cancer.
Technological advancements in field of diagnostics is also anticipated to drive the market for the forecast period. For instance, on January 2019, Nurx, a consumer health and telemedicine company, launched Home HPV Screening test. The new test allows women to conveniently and affordably check their risk for cervical cancer from the comfort of their own home.
Some of top players influencing the Global HPV and Pap Testing market:
Qiagen N.V., Abbott Laboratories, Becton, Dickinson & Company, Hologic, Inc., Quest Diagnostics, Femasys, Inc., Roche Diagnostics, Arbor Vita Corporation, Onco Health Corporation, Seegene, Inc., and others.
Apply Promo Code “STAYHOME” and Get Instant Discount of USD 1000
If you purchase the report this year:
Flat 20% instant discount
25% discount on 2nd report
15 % free customization
Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/1733
Key players operating in the global HPV testing and Pap test market include Qiagen N.V., Abbott Laboratories, Becton, Dickinson & Company, Hologic, Inc., Quest Diagnostics, Femasys, Inc., Roche Diagnostics, Arbor Vita Corporation, Onco Health Corporation, Seegene, Inc., and others. Market players are focused towards providing efficient and accurate tests at low prices to sustain their presence in the market. For instance, in April 2019, Hologic, Inc. received European CE Mark for ThinPrep Genesis processor in Europe. ThinPrep Genesis processor is an automated cytology slide and molecular sample system which allows for accurate and reliable results with increased operational efficiency.
Similarly in February 2018, Becton, Dickinson and Company received FDA approval for the BD Onclarity HPV assay, which detects and identifies HPV genotypes that put women at high risk for cervical cancer.
Contacts Us:
Direct Line: +1-206-701-6702 (US)
Web: https://www.coherentmarketinsights.com